CLYM Climb Bio, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
11:28
Aug 17
Aug 17
A news wire reports a broad list of price target cuts across multiple sectors by various banks.
A news wire reports a broad list of price target cuts across multiple sectors by various banks, alongside several coverage initiations and resumptions with new price targets, all without expressing any personal market view.
17:51
Jul 14
Jul 14
The author is compiling a list of follower-requested stocks for future review without.
The author is compiling a list of follower-requested stocks for future review without expressing any current positions or trade ideas.
LOW
07:31
Jul 05
Jul 05
The author lists 23 stocks he plans to review after receiving suggestions from followers.
The author lists 23 stocks he plans to review after receiving suggestions from followers, with no current position or directional view expressed.
LOW
19:19
Feb 04
Feb 04
Long CLYM — LLY's nondepleting mAb mechanism is a positive clinical readthrough for CLYM.
Long CLYM — LLY's nondepleting mAb mechanism is a positive clinical readthrough for CLYM, suggesting CLYM's approach aligns favorably with this finding.
MED
11:59
Jan 06
Jan 06
Competitor failure and subcutaneous edge favor CLYM
The author argues CLYM's candidate is more like Uplizna, which had strong IgG4-RD results, while competitor ZBIO failed because its construct only inhibits B cells instead of depleting them. CLYM can be administered subcutaneously versus Uplizna's IV, which the author expects to be a large commercial advantage.
HIGH
About CLYM Investor Commentary
Across the available history and selected sources, Buzzberg tracks CLYM (Climb Bio, Inc.) across 4 sources: 2 bullish vs 0 bearish calls from 4 authors. Historical directional balance: 40% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 5 total trade ideas tracked. Latest voices: DeItaone, __con_, A May MD.